Post-Traumatic Stress Disorder Market Projected to Grow at a CAGR of 12.2% Through 2034

The Post-Traumatic Stress Disorder (PTSD) market was valued at approximately USD 1.87 billion in 2025 and is projected to grow during the forecast period (2020–2034). DelveInsight's comprehensive market research provides critical insights into market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the PTSD landscape. By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The PTSD market is increasingly guided by innovative therapeutic strategies. Currently, only sertraline and paroxetine are FDA-approved medications for PTSD, representing a significant unmet need as no new treatments have been approved in over two decades. The United States accounts for approximately 90% of the total PTSD market size in the seven major markets, establishing itself as the dominant regional market.

According to DelveInsight's comprehensive “Post-Traumatic Stress Disorder (PTSD) - Market Insight, Epidemiology And Market Forecast - 2034” report, the seven major markets had 5.4 million diagnosed prevalent cases of PTSD in 2024, expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period. Furthermore, the Post-Traumatic Stress Disorder prevalence is significantly higher in women compared to men, with the United States reporting current prevalence rates of 5.2% in women and 1.8% in men. Gender differences are consistent across all major markets, with women demonstrating approximately two to two-and-a-half times higher likelihood of meeting diagnostic criteria for PTSD.

DelveInsight's report provides a comprehensive analysis of the PTSD landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines PTSD market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Post-Traumatic Stress Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, visit Post-Traumatic Stress Disorder Market Forecast

Some of the key facts of the Post-Traumatic Stress Disorder Market Report

• Key Post-Traumatic Stress Disorder Companies: COMPASS Pathways, Otsuka Pharmaceuticals, Bionomics Limited, Transcend Therapeutics, US WorldMeds, Boehringer Ingelheim, and others.
• Key Post-Traumatic Stress Disorder Therapies: Psilocybin, REXULTI (brexpiprazole) and ZOLOFT (sertraline), BNC210, Methylone (TSND-201), Lofexidine, BI 1358894, and others.
• The Post-Traumatic Stress Disorder market is expected to surge due to the increasing prevalence and awareness during the forecast period. Furthermore, launch of various multiple-stage Post-Traumatic Stress Disorder pipeline products will significantly revolutionize the Post-Traumatic Stress Disorder market dynamics.

Post-Traumatic Stress Disorder Overview

Post-Traumatic Stress Disorder (PTSD) is a seriously debilitating mental health condition that can develop in individuals who have experienced or witnessed a traumatic or life-threatening event. PTSD is characterized by symptoms including flashbacks, nightmares, severe anxiety, and uncontrollable thoughts about the traumatic event. The condition impacts approximately 13 million Americans each year, and it is estimated that nearly 7% of U.S. adults will be diagnosed with PTSD during their lifetime. PTSD can occur after various traumatic exposures and may be accompanied by significant impairment in daily functioning, frequent suicidal behavior, and high rates of comorbidity with other psychiatric conditions. Risk factors include combat exposure, physical or sexual assault, accidents, natural disasters, and other potentially traumatic events. Early diagnosis and appropriate treatment approaches, including psychotherapy and pharmacotherapy, are essential for improving patient outcomes.

Key Trends in Post-Traumatic Stress Disorder Therapeutics Market

• Limited FDA-Approved Options Creating Market Gap: Only sertraline and paroxetine have FDA approval for PTSD, with no new approvals in over 20 years, creating significant opportunities for novel therapies.
• Emergence of Rapid-Acting Neuroplastogens: Development of non-hallucinogenic neuroplastogens like TSND-201 demonstrating rapid symptom relief within 10 days, representing a paradigm shift from traditional SSRIs requiring 12 weeks.
• Psychedelic and Psychedelic-Assisted Therapies: Growing clinical investigation of psilocybin, MDMA-assisted therapy, and other psychedelic compounds, despite recent FDA setbacks.
• Precision Medicine Approaches: Increasing focus on biomarker-driven strategies and alpha-7 nicotinic receptor modulators like BNC210 targeting specific neurobiological pathways.
• Combination Therapy Development: Investigation of novel combination approaches, including brexpiprazole with sertraline, aimed at improving efficacy beyond monotherapy.
• Digital Health Integration: Expansion of teletherapy and online mental health platforms increasing access to care, particularly for underserved populations.

Post-Traumatic Stress Disorder Epidemiology

DelveInsight’s report provides a comprehensive analysis of the PTSD prevalence, incidence, and patient demographics. The highest prevalence of PTSD is observed in the 45-59 age groupfollowed by the age group of 30-44 yrs, while the lowest prevalence occurs in the early 70s. The report includes gender-specific distribution, age-related trends, severity classifications, and projections for future epidemiological patterns across the seven major markets.

Post-Traumatic Stress Disorder Epidemiology Segmentation:

The Post-Traumatic Stress Disorder market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total 12-month PTSD Prevalent Cases
• PTSD Diagnosed Prevalent Cases
• PTSD Severity-specific Cases
• PTSD Gender-specific Cases
• PTSD Age-specific Cases
• Total PTSD Treated Cases

Download the report to understand which factors are driving Post-Traumatic Stress Disorder epidemiology trends @ Post-Traumatic Stress Disorder Epidemiology Forecast

Recent Development In The PTSD Treatment Landscape

• In September 2025, Otsuka and Lundbeck received a Complete Response Letter from the FDA regarding their supplemental new drug application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD. It was concluded that efficacy had not been established based on available data, despite positive results from two of three Phase 3 trials.
• In July 2025, Transcend Therapeutics received FDA Breakthrough Therapy Designation for TSND-201 (methylone) for the PTSD treatment. The designation was based on positive results from the IMPACT-1 Phase 2 trial, which demonstrated rapid, robust, and durable improvements in PTSD symptoms, with statistically significant improvements occurring by Day 10 and sustained through Day 64. TSND-201 was well tolerated with no hallucinations or discontinuations due to adverse events.
• In February 2025, Brexpiprazole in combination with sertraline demonstrated statistically significant reduction in PTSD symptoms versus sertraline plus placebo in a Phase 3 randomized clinical trial published in JAMA.​
• In January 2025, Results from the Phase 2b ATTUNE trial of BNC210, an alpha-7 nicotinic receptor modulator developed by Bionomics, demonstrated improved PTSD symptom severity at week 12 with indications of effect as early as week 4. The trial established equipoise for additional larger trials to determine the clinical utility of BNC210 for PTSD treatment.
• In 2025, Neuphoria announced plans to launch a Phase 2b trial of BNC210 for PTSD by Q4 2025, following earlier Phase 2 studies showing improvements in core PTSD symptoms along with reductions in comorbid anxiety and sleep disturbance.
• In 2024, The FDA voted against approval of MDMA-assisted therapy for PTSD, citing concerns about trial design including blinding failure, lack of certain safety assessments (QT prolongation and abuse liability), and allegations of potential misconduct. This occurred despite Phase 3 trials demonstrating that nearly 70% of participants no longer met PTSD diagnostic criteria following treatment.

Post-Traumatic Stress Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the Post-Traumatic Stress Disorder market or expected to get launched during the study period. The analysis covers Post-Traumatic Stress Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Post-Traumatic Stress Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. The pipeline depicts a robust space with 25+ active players working to develop therapies for PTSD. Key pipeline assets include rapid-acting neuroplastogens, alpha-7 nicotinic receptor modulators, psychedelic compounds, and novel combination therapies. The report analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Post-Traumatic Stress Disorder Therapies and Key Companies

• Psilocybin: COMPASS Pathways
• REXULTI (brexpiprazole) + ZOLOFT (sertraline): Otsuka Pharmaceuticals
• BNC210: Bionomics Limited
• TSND-201 (Methylone): Transcend Therapeutics
• Lofexidine: US WorldMeds
• BI 1358894: Boehringer Ingelheim

To know more about Post-Traumatic Stress Disorder companies working in the treatment market, visit @ Post-Traumatic Stress Disorder Clinical Trials and Therapeutic Assessment

Post-Traumatic Stress Disorder Market Drivers

• Increasing prevalence of PTSD globally, particularly among women, veterans, and trauma-exposed populations, driving demand for effective therapies
• Significant unmet medical need with only two FDA-approved medications in over 20 years, creating opportunities for novel therapeutic approaches
• Growing awareness and reduced stigma around mental health conditions improving diagnosis rates and treatment-seeking behavior
• Rising healthcare expenditure and government initiatives supporting mental health programs and research funding
• Development of rapid-acting neuroplastogens and novel mechanisms of action offering paradigm shifts from traditional SSRIs
• Expansion of teletherapy and digital health platforms increasing accessibility to mental health services

Post-Traumatic Stress Disorder Market Barriers

• High discontinuation rates and regulatory setbacks for promising therapies, including FDA rejection of brexpiprazole combination and MDMA-assisted therapy
• Complex clinical trial designs and challenges in demonstrating superiority over existing approved therapies
• Limited efficacy of current FDA-approved SSRIs, with remission rates around 20-30% and delayed onset of action up to 12 weeks
• Safety concerns and potential for abuse with novel psychedelic and neuroplastogenic compounds requiring additional long-term safety data
• Underdiagnosis and underreporting of PTSD cases due to stigma and limited access to mental health professionals
• Variability in patient response due to diverse trauma types, comorbidities, and individual neurobiological differences

Scope of the Post-Traumatic Stress Disorder Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Post-Traumatic Stress Disorder Companies: COMPASS Pathways, Otsuka Pharmaceuticals, Bionomics Limited, Transcend Therapeutics, US WorldMeds, Boehringer Ingelheim, and others
• Key Post-Traumatic Stress Disorder Therapies: Psilocybin, REXULTI (brexpiprazole) and ZOLOFT (sertraline), BNC210, Methylone (TSND-201), Lofexidine, BI 1358894, and others
• Post-Traumatic Stress Disorder Therapeutic Assessment: Post-Traumatic Stress Disorder current marketed and Post-Traumatic Stress Disorder emerging therapies
• Post-Traumatic Stress Disorder Market Dynamics: Post-Traumatic Stress Disorder market drivers and Post-Traumatic Stress Disorder market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Post-Traumatic Stress Disorder Unmet Needs, KOL's views, Analyst's views, Post-Traumatic Stress Disorder Market Access and Reimbursement